...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Tumor Evasion of the Immune System by Converting CD4+CD25- T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-beta.
【24h】

Tumor Evasion of the Immune System by Converting CD4+CD25- T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-beta.

机译:通过将CD4 + CD25-T细胞转换为CD4 + CD25 + T调节细胞来逃避免疫系统的肿瘤:肿瘤衍生TGF-β的作用。

获取原文
获取原文并翻译 | 示例

摘要

CD4(+)CD25(+) T regulatory (T(reg)) cells were initially described for their ability to suppress autoimmune diseases in animal models. An emerging interest is the potential role of T(reg) cells in cancer development and progression because they have been shown to suppress antitumor immunity. In this study, CD4(+)CD25(-) T cells cultured in conditioned medium (CM) derived from tumor cells, RENCA or TRAMP-C2, possess similar characteristics as those of naturally occurring T(reg) cells, including expression of Foxp3, a crucial transcription factor of T(reg) cells, production of low levels of IL-2, high levels of IL-10 and TGF-beta, and the ability to suppress CD4(+)CD25(-) T cell proliferation. Further investigation revealed a critical role of tumor-derived TGF-beta in converting CD4(+)CD25(-) T cells into T(reg) cells because a neutralizing Ab against TGF-beta, 1D11, completely abrogated the induction of T(reg) cells. CM from a nontumorigenic cell line, NRP-152, or irradiated tumor cells did not convert CD4(+)CD25(-) T cells to T(reg) cells because they produce low levels of TGF-beta in CM. Finally, we observed a reduced tumor burden in animals receiving 1D11. The reduction in tumor burden correlated with a decrease in tumor-derived TGF-beta. Treatment of 1D11 also reduced the conversion of CD4(+) T cells into T(reg) cells and subsequent T(reg) cell-mediated suppression of antitumor immunity. In summary, we have demonstrated that tumor cells directly convert CD4(+)CD25(-) T cells to T(reg) cells through production of high levels of TGF-beta, suggesting a possible mechanism through which tumor cells evade the immune system.
机译:最初描述了CD4(+)CD25(+)T调节(T(reg))细胞在动物模型中抑制自身免疫性疾病的能力。新兴的兴趣是T(reg)细胞在癌症发展和进程中的潜在作用,因为已显示它们可抑制抗肿瘤免疫力。在这项研究中,在源自肿瘤细胞RENCA或TRAMP-C2的条件培养基(CM)中培养的CD4(+)CD25(-)T细胞具有与天然T(reg)细胞相似的特征,包括Foxp3的表达,T(reg)细胞的关键转录因子,低水平的IL-2产生,高水平的IL-10和TGF-beta以及抑制CD4(+)CD25(-)T细胞增殖的能力。进一步的研究揭示了肿瘤来源的TGF-β在将CD4(+)CD25(-)T细胞转化为T(reg)细胞中的关键作用,因为针对TGF-beta 1D11的中和抗体完全废除了对T(reg)的诱导) 细胞。来自非致瘤细胞系NRP-152或受辐射肿瘤细胞的CM不会将CD4(+)CD25(-)T细胞转换为T(reg)细胞,因为它们在CM中产生低水平的TGF-β。最后,我们观察到接受1D11的动物的肿瘤负担减少。肿瘤负荷的减少与肿瘤来源的TGF-β的减少有关。 1D11的治疗还减少了CD4(+)T细胞向T(reg)细胞的转化以及随后的T(reg)细胞介导的抗肿瘤免疫抑制作用。总之,我们已经证明,肿瘤细胞通过产生高水平的TGF-β将CD4(+)CD25(-)T细胞直接转化为T(reg)细胞,提示肿瘤细胞逃避免疫系统的可能机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号